SBT 300

Drug Profile

SBT 300

Alternative Names: SBT-300

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Singh Biotechnology
  • Class Antibodies; Antineoplastics; Skin disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Actinic keratosis; Skin cancer

Most Recent Events

  • 23 Oct 2017 Preclinical trials in Actinic keratosis in USA before October 2017 (Topical) (Singh Biotechnology pipeline, October 2017)
  • 23 Oct 2017 Preclinical trials in Skin cancer in USA before October 2017 (Topical) (Singh Biotechnology pipeline, October 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top